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ABSTRACT
Famciclovir is an antiviral with efficacy and safety comparable to aciclovir, but famciclovir’s more
favorable pharmacokinetic profile enables a less frequent dosing regimen. Future trials will likely
determine famciclovir’s role in the suppression of HBV. Infect. Dis. Obstet. Gynecol, 5:3-7, 1997.
(C) 1997 Wiley-Liss, Inc.
amciclovir (Famvir(R), SmithKlinc Beecham,
Crawley, UK) is a prodrug of the antiviral
nucleoside analog penciclovir. It is currently ap-
proved worldwide for the treatment of varicella
zoster (VCV) and herpes simplex virus (HSV-1 and
HSV-2) infections. Famciclovir is characterized by
its high rate of absorption and rapid conversion to
the active compound, penciclovir. In the U.S.., the
currently approved dosing regimen of famciclovir
for the treatment of herpes zoster (shingles) is 500
mg rid for 7 days; for recurrent genital herpes it is
125 mg bid for 5 days. This treatment is also ef-
fective for treatment of first episode genital herpes
at a dose of 250 mg rid for 5 days and chronic
suppression of recurrences at a dose of 250 mg bid.
However, the last two indications are still pending
approval by U.S. regulatory authorities.
STRUCTURE AND DERIVATION
Famciclovir (2-[2-(2-amino-9H-purin-9-yl)ethyl]-
1,3-propanediol diacetate) is the diacetyl ester of
6-deoxy penciclovir (a synthetic acyclic guanine
derivative). Whereas penciclovir itself is very
poorly absorbed orally, it was found in animal stud-
ies that its dipropionyl and diacetyl 6-deoxy deriva-
tives (BRL 43599 and famciclovir, respectively)
gave much improved blood levels of penciclovir.
Furthermore, famciclovir was found to be much
more stable than BRL 43599.1 Human studies con-
firmed that, after oral dosing with famciclovir, more
than half the dose is absorbed.
MECHANISM OF ACTION
Penciclovir freely enters both virus-infected and
uninfected cells. However, antiherpesviral selectiv-
ity relies on rapid phosphorylation to the active
form, penciclovir triphosphate, in virus-infected
cells only. Viral thymidine kinase (TK) is respon-
sible for the critical rate-limiting initial phosphor-
ylation to penciclovir monophosphate. Metabolism
to the diphosphate and active triphosphate forms
occur via other cellular enzymes,z
Penciclovir triphosphate accumulates to high
concentrations in virus-infected cells and interacts
with viral DNA polymerase to inhibit viral DNA
synthesis.
3 Although penciclovir is phosphorylated
in uninfected cells as well, conversion to penciclo-
vir monophosphate is much more readily achieved
by viral than by human TK. Thus, concentrations
of penciclovir triphosphate remain low in unin-
fected cells and have minimal effect on human
DNA. z
PHARMACOKINETICS
After oral administration, famciclovir undergoes
rapid and extensive absorption in the upper intes-
tine and is rapidly metabolized in the intestinal
wall and liver to the active compound penciclo-
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vir.4,s Little or no famciclovir is detected in plasma
or urine. Inactive metabolites formed include 6-
deoxy penciclovir, monoacetylated penciclovir, and
6-deoxy monoacetylated penciclovir.
6 Unlike aci-
clovir, which has a 10-20% bioavailability, 7 the bio-
availability of penciclovir after oral administration
of famciclovir is about 77%.4,8,9 Compared to aci-
clovir, penciclovir is preferentially taken up and
phosphorylated by HSV- and VZV-infected cells.
Furthermore, penciclovir triphosphate has a very
prolonged intracellular half-life in infected cells (7
to 20 hours versus 0.7 to hour for aciclovir tri-
phosphate), z Penciclovir is not metabolized but is
eliminated unchanged in the urine.1
The pharmacokinetics of penciclovir remain
largely unaltered in the elderly, making it unnec-
essary to adjust the dosage in these patients.TM
In a study of patients with renal impairment,
urinary excretion of pcnciclovir decreased in pro-
portion to the decrease in estimated creatine clear-
ance leading to a recommendation that the dosage
interval of famciclovir should be prolonged from 8
hours to 12 hours for patients with moderate renal
impairment, and to 24 hours for patients with se-
vere renal impairment.
13 There is no evidence for
the need to alter dosage levels of famciclovir in
those with well-compensated hepatic impair-
merit.4 The pharmacokinetics of famciclovir have
not been studied in patients with severe uncom-
pensated hepatic impairment.
In three studies that investigated the effects of
food on the pharmacokinetics and bioavailability of
famciclovir,S-17 no clinically significant differ-
ences were observed in healthy male volunteers
who received famciclovir (250 and 500 mg single
doses) 30 minutes after food compared to those
who received famciclovir 2 hours before food.
When famciclovir 250 mg was administered 30
minutes after food, Cma was reduced by only 20%.
SIDE EFFECTS AND INTERACTIONS
Tolerability data from trials of famciclovir for the
treatment of genital herpes and herpes zoster indi-
cate that famciclovir is well tolerated with an ad-
verse event profile similar to placebo. e’ls In an
analysis of several trials, side effects did not corre-
late with increasing daily dose over a range of 125
rag/day to 2,250 rag/day. The most frequent ad-
verse events reported in this analysis were head-
ache, nausea, and diarrhea, which occurred in >2%
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of patients in both famciclovir and placebo groups.
Serious adverse events were no more frequent than
placebo and none were classified as related to or
probably related to famciclovir.7
In a recent dose-finding trial of twice-daily oral
famciclovir for recurrent genital herpes,
19 there
were no significant differences in adverse events or
withdrawals between the famciclovir (125,250, and
500 mg twice-daily) and placebo groups. Most fre-
quent adverse effects reported for both groups
were headache, nausea, and dizziness.
A recent double-blind placebo-controlled study
in which 34 men with recurrent genital herpes re-
ceived famciclovir 250 mg twice daily for 18 weeks
reported that famciclovir did not appear to have
significant effects on any of the sperm parameters
measured,zo
No clinically significant alterations in penciclo-
vir pharmacokinetics were observed following
single-dose administration of 500 mg famciclovir
after pre-treatment with multiple doses of cimeti-
dine, allopurinol, or theophylline.
6
SPECTRUM OF ANTIVIRAL ACTIVITY
Famciclovir is effective against HSV-1, HSV-2,
VCV, and the Epstein-Barr virus (EBV). Penciclo-
vir has also been shown to inhibit viral replication
in vitro in duck hepatocytes infected with duck
hepatitis B virus (HBV) z,za and famciclovir has
been shown to inhibit HBV replication in vivo in
hepatic and nonhepatic tissue of ducklings that had
been infected in ovo with duck HBV.zz
CLINICAL APPLICATIONS
Famciclovir is currently licensed to treat VZV her-
pes zoster (shingles) and HSV genital herpes infec-
tions.
Two large clinical trials evaluated famciclovir’s
effect on rash healing of acute herpes zoster and
control of acute pain. A prospective, randomized,
placebo-controlled, double-blind trial evaluated
famciclovir (500 or 750 mg three times daily for 7
days) in 419 intent-to-treat immunocompetent pa-
tients with herpes zoster rash.z3 Famciclovir accel-
erated the healing of skin lesions (reduced times to
full crusting and loss of vesicles, ulcers, and crusts)
compared to those given placebo and significantly
reduced duration of viral shedding and pain. More
importantly, patients receiving famciclovir lost
post-herpetic neuralgia (PHN; defined as pain per-FAMCICL0VIR (FAMVIR(R)) SACKS
sisting after lesion healing) a median of approxi-
mately 60 days sooner than those on placebo.
A double-blind, double-dummy, randomized
study compared the safety and efficacy of famci-
clovir (250, 500, or 750 mg three times a day) and
aciclovir (800 mg five times a day) for 7 days in 545
immunocompetent patients with acute herpes zos-
ter.z4 For the intent-to-treat population, all doses of
famciclovir were equally effective as aciclovir for
healing lesions and shortening the time to loss of
acute pain. With early treatment, there was ap-
proximately 1.5-1.8-fold acceleration in loss of pain
over aciclovir, reinforcing the potential benefit of
early treatment.
To determine the efficacy and safety of famci-
clovir in the episodic treatment of recurrent genital
herpes, a multicenter, randomized, double-blind,
dose-ranging, patient-initiated study was con-
ducted comparing three twice-daily doses (125,
250, and 500 mg) of oral famciclovir with placebo
over a 5-day period.
18 Famciclovir at all doses was
significantly more effective than placebo at ’reduc-
ing time to healing, time to cessation of viral shed-
ding, as well as durations of lesion edema, vesicles,
ulcer, and crusts. Times to cessation of all symp-
toms and of moderate to severe lesion tenderness,
pain, and burning were also reduced. Patients who
initiated famciclovir prior to viral shedding more
frequently aborted the onset of viral shedding. All
doses were equally effective and well tolerated.
A similar multicentre, clinic-initiated trial using
oral famciclovir at the same three doses again dem-
onstrated reductions of viral shedding, lesion dis-
comfort, lesion duration, and new lesion formation
in famciclovir-treated (all doses) patients,zs Lesion
tenderness, itching, edema, and ulcer duration
were also significantly reduced, and culture posi-
tive new lesions were more frequently avoided.
Recent trials have also shown favourable results
with famciclovir for both the treatment of first epi-
sode genital herpes and for the suppression of re-
current genital herpes,z6 although these are not
currently licensed indications in North America.
Optimal dosing of famciclovir for first episodes was
250 mg tid, while for suppression, optimal dosing
was 250 mg bid, and while for suppression, optimal
dosing was 250 mg bid.z7
In a double-blind, placebo-controlled pilot
study of 17 patients with chronic HBV infection,
famciclovir (250 mg or 500 mg three times daily)
TABLE I. Costs of selected antiviral agents
(in U.S. dollars)
Tablets/
Cost/ course of
Product Dose dose therapy
Cost of
therapy
Zoster
Famvir
Aciclovir
Valaciclovir
Recurrent GH
Famciclovir
Aciclovir
Valaciclovir
st Episode
GH
Famciclovir
(under FDA
review)
Aciclovir
Valaciclovir
(under FDA
review)
500 mg tid/
7 days $4.92 21
800 mg
5x/day
7 days: $3.41 35
10 days: $3.41 50
1000 mg
tid/7 day $4.60 42
125 mg bid/
5 days $1.85
200 mg
5x/day
5 days $0.90
400 mg tid/
5 days $1.76
500 rng bid/
5 days $2.30
250 mg tid/
5 days $2.45
200 mg
5x/day/
10 days $0.90
800 mg tid
7 days $3.41
1000 mg
bid/5
days $4.60
$103.32
$119.35
$170.50
$96.60
10 $18.50
25 $22.50
15 $26.40
tO $23.00
15 $36.75
50 $45.00
21 $71.61
20 $46.00
aAIternative CDC recommended dose/non FDA approved.
was found to cause a 90% decrease in levels of
HBV-DNA in six patients on the drug.zs This ef-
fect was maintained in four patients throughout the
10-day treatment period. Famciclovir alone,z9,3 or
in combination with prostaglandin E,31 has also
been used successfully to suppress HBV replica-
tion in liver transplant patients. Further studies are
required in HBV, however, before clinical indica-
tions, if any, can be determined.
COST
Table presents the comparative costs to the pa-
tient in the US for the antivirals famciclovir, aci-
clovir, and valaciclovir.
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